Veracyte, Inc. · NASDAQ:VCYT
Veracyte — Q1 2025 Earnings Presentation
24 slides from Veracyte's earnings presentation, May 7, 2025
Slide 1: © 2025 Veracyte, Inc. All rights reserved.
© 2025 Veracyte, Inc. All rights reserved. 1
Slide 2: © 2025 Veracyte, Inc. All rights reserved.
‐ ‐ ‐ © 2025 Veracyte, Inc. All rights reserved. 2
Slide 3: © 2025 Veracyte, Inc. All rights reserved.
© 2025 Veracyte, Inc. All rights reserved. 3
Slide 4: © 2025 Veracyte, Inc. All rights reserved.
© 2025 Veracyte, Inc. All rights reserved. 4
Slide 5: © 2025 Veracyte, Inc. All rights reserved.
© 2025 Veracyte, Inc. All rights reserved. 5
Slide 6: © 2025 Veracyte, Inc. All rights reserved.
© 2025 Veracyte, Inc. All rights reserved. 6
Slide 7: © 2025 Veracyte, Inc. All rights reserved.
• • • • • • • © 2025 Veracyte, Inc. All rights reserved. 7
Slide 8: Testing volume by quarter
10% 16,300 15,700 15,200 15,100 14,000 13,500 13,000 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 © 2025 Veracyte, Inc. All rights reserved. 8
Slide 9: © 2025 Veracyte, Inc. All rights reserved.
© 2025 Veracyte, Inc. All rights reserved. 9
Slide 10: © 2025 Veracyte, Inc. All rights reserved.
© 2025 Veracyte, Inc. All rights reserved. 10
Slide 11: © 2025 Veracyte, Inc. All rights reserved.
© 2025 Veracyte, Inc. All rights reserved. 11
Slide 12: © 2025 Veracyte, Inc. All rights reserved.
• • • • • • © 2025 Veracyte, Inc. All rights reserved. 12
Slide 13: © 2025 Veracyte, Inc. All rights reserved.
© 2025 Veracyte, Inc. All rights reserved. 13
Slide 14: © 2025 Veracyte, Inc. All rights reserved.
© 2025 Veracyte, Inc. All rights reserved. 14
Slide 15: © 2025 Veracyte, Inc. All rights reserved.
© 2025 Veracyte, Inc. All rights reserved. 15
Slide 16: © 2025 Veracyte, Inc. All rights reserved.
© 2025 Veracyte, Inc. All rights reserved. 16
Slide 17: © 2025 Veracyte, Inc. All rights reserved.
© 2025 Veracyte, Inc. All rights reserved. 17
Slide 18: © 2025 Veracyte, Inc. All rights reserved.
© 2025 Veracyte, Inc. All rights reserved. 18
Slide 19: © 2025 Veracyte, Inc. All rights reserved.
© 2025 Veracyte, Inc. All rights reserved. 19
Slide 20: Non-GAAP cost of revenue reconciliation
(Unaudited) (In thousands of dollars) Three Months Ended Dec 31, 2023 Mar 31, 2024 Jun 30, 2024 Sep 30, 2024 Dec 31, 2024 Mar 31, 2025 GAAP cost of testing revenue $ 24,105 $ 25,979 $ 27,920 $ 29,029 $ 31,645 $ 28,260 Stock-based compensation expense (392) (390) (497) (524) (562) (446) Acquisition r
Slide 21: Non-GAAP operating expense reconciliation
(Unaudited) (In thousands of dollars) Three Months Ended Dec 31, 2023 Mar 31, 2024 Jun 30, 2024 Sep 30, 2024 Dec 31, 2024 Mar 31, 2025 GAAP research and development $ 18,673 $ 15,965 $ 16,465 $ 17,574 $ 19,290 $ 17,720 Stock-based compensation expense (1,495) (1,763) (1,895) (1,957) (1,896) (2,066)
Slide 22: Adjusted EBITDA reconciliation, quarterly
(Unaudited) (In thousands of dollars) Three Months Ended Dec 31, 2023 Mar 31, 2024 Jun 30, 2024 Sep 30, 2024 Dec 31, 2024 Mar 31, 2025 GAAP Net Income (Loss) $ (28,293) $ (1,864) $ 5,734 $ 15,155 $ 5,113 $ 7,047 GAAP Net Income (Loss) as a % of Revenue (28.8 %) (1.9 %) 5.0 % 13.1 % 4.3 % 6.2 % Amort
Slide 23: Adjusted EBITDA reconciliation, twelve months
(Unaudited) (In thousands of dollars) Twelve Months Ended Dec 31, 2024 GAAP Net Income (Loss) $ 24,138 GAAP Net Income (Loss) as a % of Revenue 5.4 % Amortization of intangible assets 14,849 Depreciation expense 8,610 Stock-based compensation expense 36,249 Acquisition related expenses (1) 6,631 Oth
Slide 24: Non-GAAP net income and EPS reconciliation
(Unaudited) (In thousands of dollars) Three Months Ended Dec 31, 2023 Mar 31, 2024 Jun 30, 2024 Sep 30, 2024 Dec 31, 2024 Mar 31, 2025 GAAP Net Income (Loss) $ (28,293) $ (1,864) $ 5,734 $ 15,155 $ 5,113 $ 7,047 Amortization of intangible assets 4,563 3,653 3,790 3,797 3,609 3,207 Stock-based compen